Triple Therapy Shows Promise for Rare Neuroendocrine Cancer
A clinical trial reports a 69.8% objective response rate for advanced extrapulmonary neuroendocrine carcinoma.
Updated on Oct. 23, 2026 in Cancer
A combination of surufatinib, serplulimab, and chemotherapy demonstrated an objective response rate of 69.8% in patients with advanced extrapulmonary neuroendocrine carcinoma as of May 30, 2026. The regimen achieved a 95.3% disease control rate among the study cohort.
Why it matters
This combination treatment utilizes the antiangiogenic and immunomodulatory properties of surufatinib alongside the PD-1 blocking effects of serplulimab to address complex tumor sites. The findings suggest a new therapeutic pathway for cancers typically resistant to standard care.
The study reported a median progression-free survival of 9.4 months and a median response duration of 9.1 months. Patients received a daily 250 mg dose of surufatinib and 300 mg of serplulimab every three weeks.
The players
ESMO Congress
This is a major international medical conference held annually to showcase the latest advancements in oncology research and clinical trials.
The details
Researchers evaluated 53 enrolled patients with primary tumors frequently located in the intestine, stomach, and pancreas. Tumors were monitored every six weeks using RECIST 1.1 assessment criteria to track patient progress.
Timeline
Data for the clinical trial results were cut off on May 30, 2026.
Findings were presented at the ESMO Congress on October 23, 2026.
The Big Picture
The study utilizes the RECIST 1.1 criteria to provide a standardized framework for assessing the effectiveness of the experimental treatment. This adherence ensures that findings remain comparable to global oncological benchmarks used in solid tumor research.
Patients with advanced neuroendocrine carcinoma may see new therapeutic options emerge as these trial results move toward potential clinical integration. Medical providers can look to these outcomes to understand how combined immunotherapy and chemotherapy regimens influence treatment planning.
The takeaway
This study highlights the potential of multi-drug regimens in managing advanced malignancies that have previously proven difficult to treat. Clinicians and patients should await final survival data to determine the long-term efficacy of this specific combination approach.
What happens next
Mature survival data are expected to be released following the conclusion of the ongoing clinical trial enrollment phase.
Further reading
Learn more about the latest research and standard treatment protocols in the Cancer section.
More information
View the full clinical trial study details on the official registry.
